Home / Business and Economy / Novo Nordisk Alzheimer's Trial Fails to Slow Decline
Novo Nordisk Alzheimer's Trial Fails to Slow Decline
24 Nov
Summary
- Novo Nordisk's Alzheimer's trial did not meet its primary goal.
- Semaglutide, used in Ozempic and Wegovy, showed no delay in disease progression.
- The drug company's stock fell over 11% following the trial results.
Novo Nordisk announced that a crucial clinical trial for Alzheimer's disease has unfortunately missed its primary objective. The trial focused on semaglutide, the active compound found in the widely successful Ozempic and Wegovy medications, aiming to determine if it could slow the progression of Alzheimer's.
Despite observing positive effects on certain Alzheimer's disease-related biomarkers in separate studies, the main trial's results indicated no significant delay in cognitive decline. The trial's target was to reduce patient decline by at least 20%, a benchmark that was not met.
Following this announcement, Novo Nordisk's shares experienced a notable decline, dropping as much as 11% in early trading. Analysts had previously considered the trials a long shot, with the company itself likening the potential outcome to winning a 'lottery ticket'.
